InsidersTradesSigma
Follow the Nasus Pharma Ltd share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €42.7m. The latest transaction was disclosed on 22 April 2026 (Acquisition). Among the most active insiders: Teleman Dan Benjamin. All data is free.
Analysts rate Nasus Pharma Ltd Buy (bullish), based on 3 analysts. Average price target: US$19.67.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Nasus Pharma Ltd is a company focused on developing innovative treatments for respiratory diseases. It is listed on the XNAS market.